US 12,448,382 B2
Heterocyclic compounds for mediating tyrosine kinase 2 activity
Xiangyang Chen, Beijing (CN); and Yucheng Pang, Beijing (CN)
Assigned to Guangzhou Innocare Pharma Tech Co. Ltd., Guangzhou (CN)
Filed by GUANGZHOU INNOCARE PHARMA TECH CO., LTD., Guangzhou (CN)
Filed on Dec. 22, 2021, as Appl. No. 17/559,330.
Application 17/559,330 is a continuation of application No. PCT/CN2020/098105, filed on Jun. 24, 2020.
Claims priority of application No. 201910572091.9 (CN), filed on Jun. 28, 2019.
Prior Publication US 2022/0112200 A1, Apr. 14, 2022
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 21 Claims
 
1. A compound of Formula (I), or a pharmaceutical acceptable salt, stable isotope, stereoisomer thereof:

OG Complex Work Unit Chemistry
wherein:
R1 is aryl or heteroaryl, where one or more hydrogens of the aryl and heteroaryl are optionally substituted by D, halogen, cyano, —ORb, —NRbRc, —COORb, —C(O)Rb, —NRbC(O)Rc, —C(O)NRbRc, —S(O)2Rb, —S(O)2NRbRc, —S(O)(NRb)Rc, —P(O)(CH3)2, C1-6 alkyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclyl or 5- to 6-membered heteroaryl;
R2 is H, D or —NHRa;
R3 is H, D, halogen, cyano, C1-6 alkyl, C3-6 cycloalkyl or OC1-6 alkyl, where one or more hydrogens of the alkyl and cycloalkyl are optionally substituted by D or F;
R4 and R5 are independently selected from H, D, halogen, C1-6 alkyl or OC1-6 alkyl, where one or more hydrogens of the alkyl are optionally substituted by D or F;
R6 and R7 are independently selected from H, D, cyano or C1-6 alkyl, where one or more hydrogens of the alkyl is optionally substituted by D or F, or R6 and R7 combine as oxo;
L is a bond, C1-6 alkylene, —C(O)—, —C(O)O—, —C(O)N(Ra)—, —S(O)2— or —S(O)2N(Ra)—;
A is H, C1-6 alkyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclyl, aryl or heteroaryl, where one or more hydrogens of the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by D, halogen, cyano, —ORd, —NRdRe, C1-6 alkyl, C3-6 cycloalkyl or 3- to 8-membered heterocyclyl;
Ra is H, C1-6 alkyl or C3-6 cycloalkyl, where one or more hydrogens of the alkyl and cycloalkyl are optionally substituted by D or F;
Rb and Rc are independently selected from H, C1-6 alkyl, C3-6 cycloalkyl or 3- to 8-membered heterocyclyl containing N and/or O, where one or more hydrogens of the alkyl, cycloalkyl and heterocyclyl are optionally further substituted by D, halogen, CN, —OH, —NH2, C1-6 alkyl and —OC1-6 alkyl, and
Rd and Rc are independently selected from H, C1-6 alkyl, C3-6 cycloalkyl or 3- to 8-membered heterocyclyl, where one or more hydrogens of the alkyl, cycloalkyl and heterocyclyl are optionally further substituted by D or F.